Semaglutide in Australia: GLP-1 Research Guide

Semaglutide is a synthetic GLP-1 receptor agonist developed by Novo Nordisk, structurally based on native glucagon-like peptide-1 (GLP-1) with modifications that extend its half-life to approximately one week. It is best known from the SUSTAIN (diabetes) and STEP (obesity) clinical trial programmes, in which it produced substantial reductions in body weight and improvements in metabolic markers.

GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and, critically for weight research, reduces appetite via central and peripheral mechanisms including action on hypothalamic GLP-1 receptors.

Semaglutide's modifications include substitution of alanine at position 8 (conferring DPP-4 resistance), addition of a C18 fatty diacid chain linked via a linker to lysine at position 26 (enabling albumin binding and extending half-life), and an Arg34Lys substitution. These changes produce a molecule with high GLP-1 receptor selectivity and a ~168-hour half-life, enabling once-weekly dosing in clinical settings.

The STEP programme (Semaglutide Treatment Effect in People with Obesity) represents the most comprehensive clinical dataset for any GLP-1 compound to date:

• STEP 1, 68-week RCT (n=1,961): 2.4mg weekly semaglutide produced mean body weight reduction of 14.9% vs 2.4% placebo
• STEP 2, participants with type 2 diabetes: 9.6% weight loss vs 3.4% placebo at 68 weeks
• STEP 3, intensive behavioural therapy plus semaglutide: 16.0% weight reduction
• STEP 4, withdrawal study: participants discontinuing semaglutide regained approximately two-thirds of lost weight within one year, suggesting ongoing administration is required to maintain effects

Beyond weight, semaglutide has been studied for cardiovascular outcomes (SELECT trial), non-alcoholic steatohepatitis (NASH), chronic kidney disease, and neurodegenerative disease models. The SELECT trial (n=17,604) demonstrated 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease.

GLP-1 receptors (GLP-1R) are G protein-coupled receptors (GPCRs) expressed in the pancreas, brain, heart, kidneys, gastrointestinal tract, and adipose tissue. Semaglutide's primary pharmacological actions include:

• Pancreatic beta cells, glucose-dependent insulin secretion; GLP-1R stimulation potentiates insulin release only in the presence of elevated glucose (minimising hypoglycaemia risk)
• Alpha cells, suppression of postprandial glucagon, reducing hepatic glucose output
• Hypothalamus and brainstem, activation of GLP-1R in the arcuate nucleus and area postrema reduces appetite and increases satiety signalling
• Gastric motility, delayed gastric emptying extends nutrient absorption time and amplifies satiety signalling
• Cardiac and vascular, GLP-1R agonism has direct cardioprotective effects independent of weight loss, including reduced inflammation and improved endothelial function

Semaglutide's clinical success opened a research programme into dual and triple incretin agonists with progressively greater weight-loss effect sizes:

From a receptor pharmacology standpoint, the progression from single (GLP-1R) to dual (GLP-1R + GIPR) to triple (GLP-1R + GIPR + GCGR) agonism represents an attempt to engage complementary energy-expenditure and appetite-regulation pathways simultaneously. Tirzepatide and retatrutide extend semaglutide's foundation while adding GIP and glucagon receptor activity respectively.

OzPeps stocks research-grade Tirzepatide and Retatrutide for in-vitro laboratory research.

An emerging body of preclinical and early clinical data suggests GLP-1 receptor signalling has broad applications beyond diabetes and obesity:

• Neurodegeneration, GLP-1R expression in the substantia nigra and hippocampus; preclinical data in Parkinson's and Alzheimer's models showing neuroprotective effects (MEND trial with semaglutide in Parkinson's disease: Phase 2 results)
• Addiction models, GLP-1R agonism has been shown to reduce alcohol and opioid self-administration in rodent models; clinical signals emerging for alcohol use disorder
• MASH/NASH, semaglutide Phase 2 showed resolution of NASH in 59% vs 17% placebo; Phase 3 ESSENCE trial ongoing
• Chronic kidney disease, FLOW trial (semaglutide) showed 24% reduction in kidney disease progression and 38% reduction in kidney failure
• Inflammation, GLP-1R agonists reduce CRP, IL-6, and TNF-α; mechanisms under investigation

Semaglutide for research use is available as a lyophilised powder requiring reconstitution with bacteriostatic water prior to use. Research protocols typically use bacteriostatic water (0.9% benzyl alcohol) rather than sterile water to extend post-reconstitution stability.

General research-context reconstitution notes:

• Reconstituted GLP-1 peptides should be stored at 2–8°C and protected from light
• Use the OzPeps reconstitution calculator to determine volumes for your target concentration
• Bacteriostatic water is available from OzPeps for use with peptide reconstitution

OzPeps does not currently stock semaglutide. For researchers studying GLP-1 pathway pharmacology, the following related compounds are available:

• Tirzepatide 30mg, dual GLP-1R/GIPR agonist; see tirzepatide research guide →
• Retatrutide 20mg, triple GLP-1R/GIPR/GCGR agonist; see retatrutide research guide →
• Retatrutide 30mg, larger vial option for extended research protocols

Both tirzepatide and retatrutide engage the GLP-1 receptor and provide meaningful mechanistic overlap with semaglutide research, while additionally activating complementary incretin and glucagon pathways.

Semaglutide is TGA-approved as a prescription medicine in Australia (under brand names Ozempic and Wegovy) for specific clinical indications, meaning it is a Schedule 4 prescription-only medicine and not available for general supply without a prescription. Research-grade semaglutide supplied for laboratory use falls under different regulatory considerations than therapeutic supply.

OzPeps supplies all research compounds strictly for in-vitro laboratory and scientific research use only, not for human or animal consumption. Researchers are responsible for all applicable regulatory compliance in their jurisdiction. See the Australian peptide legality research guide → for a detailed overview.